Telmisartan Teva Pharma

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
26-10-2021

Ingredient activ:

Telmisartan

Disponibil de la:

Teva B.V.

Codul ATC:

C09CA07

INN (nume internaţional):

telmisartan

Grupul Terapeutică:

Agents acting on the renin-angiotensin system

Zonă Terapeutică:

Hypertension

Indicații terapeutice:

Treatment of essential hypertension in adults.

Rezumat produs:

Revision: 10

Statutul autorizaţiei:

Authorised

Data de autorizare:

2011-10-03

Prospect

                                44
B. PACKAGE LEAFLET
45
PACKAGE LEAFLET: INFORMATION FOR THE USER
TELMISARTAN TEVA PHARMA 20 MG TABLETS
Telmisartan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Telmisartan Teva Pharma is and what it is used for
2.
What you need to know before you take Telmisartan Teva Pharma
3.
How to take Telmisartan Teva Pharma
4.
Possible side effects
5.
How to store Telmisartan Teva Pharma
6.
Contents of the pack and other information
1.
WHAT TELMISARTAN TEVA PHARMA IS AND WHAT IT IS USED FOR
Telmisartan Teva Pharma belongs to a class of medicines known as
angiotensin-II receptor antagonists.
Angiotensin II is a substance occurring in the body, which causes your
blood vessels to narrow, thus
increasing your blood pressure. Telmisartan Teva Pharma blocks this
effect of angiotensin II so that the
blood vessels relax, and your blood pressure is lowered.
Telmisartan Teva Pharma is used to treat essential hypertension (high
blood pressure) in adults. ‘Essential’
means that the high blood pressure is not caused by any other
condition.
High blood pressure, if not treated, can damage blood vessels in
several organs, which could lead sometimes
to heart attacks, heart or kidney failure, strokes or blindness. There
are usually no symptoms of high blood
pressure before damage occurs. Thus it is important to regularly
measure blood pressure to verify if it is
within the normal range.
Telmisartan Teva Pharma is also used to reduce cardiovascular events
(i.e. heart attack or stroke) in adults
who are at risk becaus
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Telmisartan Teva Pharma 20 mg tablets
Telmisartan Teva Pharma 40 mg tablets
Telmisartan Teva Pharma 80 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Telmisartan Teva Pharma 20 mg tablets
Each tablet contains 20 mg telmisartan.
Telmisartan Teva Pharma 40 mg tablets
Each tablet contains 40 mg telmisartan.
Telmisartan Teva Pharma 80 mg tablets
Each tablet contains 80 mg telmisartan.
Excipients with known effect
Telmisartan Teva Pharma 20 mg tablets
Each tablet contains 21.4 mg sorbitol (E420)
Telmisartan Teva Pharma 40 mg tablets
Each tablet contains 42.8 mg sorbitol (E420)
Telmisartan Teva Pharma 80 mg tablets
Each tablet contains 85.6 mg sorbitol (E420)
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Telmisartan Teva Pharma 20 mg tablets
White to off white, oval shaped tablet; one side of the tablet is
debossed with the number
"93". The other side of the tablet is debossed with the number "7458".
Telmisartan Teva Pharma 40 mg tablets
White to off white, oval shaped tablet; one side of the tablet is
debossed with the number
"93". The other side of the tablet is debossed with the number "7459".
Telmisartan Teva Pharma 80 mg tablets
White to off white, oval shaped tablet; one side of the tablet is
debossed with the number
"93". The other side of the tablet is debossed with the number "7460".
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Hypertension
Treatment of essential hypertension in adults.
3
Cardiovascular prevention
Reduction of cardiovascular morbidity in adults with:
•
manifest atherothrombotic cardiovascular disease (history of coronary
heart disease, stroke, or peripheral
arterial disease) or
•
type 2 diabetes mellitus with documented target organ damage
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Treatment of essential hypertension
The usually effective dose is 40 mg once daily. Some patients may
already benefit at a daily dose of 20 mg.
In cases where the target blood 
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului bulgară 26-10-2021
Raport public de evaluare Raport public de evaluare bulgară 19-06-2015
Prospect Prospect spaniolă 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului spaniolă 26-10-2021
Raport public de evaluare Raport public de evaluare spaniolă 19-06-2015
Prospect Prospect cehă 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului cehă 26-10-2021
Raport public de evaluare Raport public de evaluare cehă 19-06-2015
Prospect Prospect daneză 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului daneză 26-10-2021
Raport public de evaluare Raport public de evaluare daneză 19-06-2015
Prospect Prospect germană 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului germană 26-10-2021
Raport public de evaluare Raport public de evaluare germană 19-06-2015
Prospect Prospect estoniană 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului estoniană 26-10-2021
Raport public de evaluare Raport public de evaluare estoniană 19-06-2015
Prospect Prospect greacă 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului greacă 26-10-2021
Raport public de evaluare Raport public de evaluare greacă 19-06-2015
Prospect Prospect franceză 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului franceză 26-10-2021
Raport public de evaluare Raport public de evaluare franceză 19-06-2015
Prospect Prospect italiană 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului italiană 26-10-2021
Raport public de evaluare Raport public de evaluare italiană 19-06-2015
Prospect Prospect letonă 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului letonă 26-10-2021
Raport public de evaluare Raport public de evaluare letonă 19-06-2015
Prospect Prospect lituaniană 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului lituaniană 26-10-2021
Raport public de evaluare Raport public de evaluare lituaniană 19-06-2015
Prospect Prospect maghiară 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului maghiară 26-10-2021
Raport public de evaluare Raport public de evaluare maghiară 19-06-2015
Prospect Prospect malteză 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului malteză 26-10-2021
Raport public de evaluare Raport public de evaluare malteză 19-06-2015
Prospect Prospect olandeză 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului olandeză 26-10-2021
Raport public de evaluare Raport public de evaluare olandeză 19-06-2015
Prospect Prospect poloneză 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului poloneză 26-10-2021
Raport public de evaluare Raport public de evaluare poloneză 19-06-2015
Prospect Prospect portugheză 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului portugheză 26-10-2021
Raport public de evaluare Raport public de evaluare portugheză 19-06-2015
Prospect Prospect română 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului română 26-10-2021
Raport public de evaluare Raport public de evaluare română 19-06-2015
Prospect Prospect slovacă 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului slovacă 26-10-2021
Raport public de evaluare Raport public de evaluare slovacă 19-06-2015
Prospect Prospect slovenă 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului slovenă 26-10-2021
Raport public de evaluare Raport public de evaluare slovenă 19-06-2015
Prospect Prospect finlandeză 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului finlandeză 26-10-2021
Raport public de evaluare Raport public de evaluare finlandeză 19-06-2015
Prospect Prospect suedeză 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului suedeză 26-10-2021
Raport public de evaluare Raport public de evaluare suedeză 19-06-2015
Prospect Prospect norvegiană 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului norvegiană 26-10-2021
Prospect Prospect islandeză 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului islandeză 26-10-2021
Prospect Prospect croată 26-10-2021
Caracteristicilor produsului Caracteristicilor produsului croată 26-10-2021
Raport public de evaluare Raport public de evaluare croată 19-06-2015

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor